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Abstract: Brugada syndrome is an inherited, rare cardiac arrhythmogenic disease, associated 
with sudden cardiac death. It accounts for up to 20% of sudden deaths in patients without 
structural cardiac abnormalities. The majority of mutations involve the cardiac sodium channel 
gene SCN5A and give rise to classical abnormal electrocardiogram with ST segment elevation 
in the right precordial leads V1 to V3 and a predisposition to ventricular fibrillation. The 
pathophysiological mechanisms of Brugada syndrome have been investigated using model 
systems including transgenic mice, canine heart preparations, and expression systems to study 
different SCN5A mutations. These models have a number of limitations. The recent 
development of pluripotent stem cell technology creates an opportunity to study 
cardiomyocytes derived from patients and healthy individuals. To date, only a few studies have 
been done using Brugada syndrome patient-specific iPS-CM, which have provided novel 
insights into the mechanisms and pathophysiology of Brugada syndrome. This review provides 
an evaluation of the strengths and limitations of each of these model systems and summarizes 
the key mechanisms that have been identified to date. 
Keywords: Brugada syndrome; SCN5A; model systems; induced pluripotent stem cells (iPS) 
 
1. Introduction 
The Brugada syndrome, first described by the Brugada brothers in 1992[1], is a life-
threatening arrhythmogenic disease characterized by an abnormal electrocardiogram (Figure 1) 
with ST segment elevation in the right precordial leads V1 to V3 and right bundle-branch block. 
It is responsible for 4 to 12% of sudden cardiac deaths in the general population. The Brugada 
syndrome is an inherited disease typically transmitted in an autosomal-dominant manner with 
incomplete penetrance. Patients often present with symptoms of ventricular tachycardia, 
bradycardia, or atrial-ventricular (AV) node conduction disorder. These symptoms are more 
often present in males than in females.  
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Figure 1. The electrocardiogram in the Brugada syndrome. (A) Schematic diagram of a normal 
electrocardiographic complex representing sinus rhythm. (B) Precordial leads V1-V3 from a 
normal electrocardiogram. (C) Precordial leads V1-V3 from a patient with Brugada syndrome. 
Brugada syndrome was initially proposed as a primary electrical disease in structurally 
normal heart [2,3]. However structural abnormalities found in the right ventricle outflow tract 
(RVOT) of patients suggest that Brugada syndrome may belong to a larger spectrum of right 
ventricular cardiomyopathie [4]. 
To date, the implantation of a cardioverter defibrillator is the only effective treatment for the 
conditio [5,6]. The clinical phenotype and its manifestations have been reviewed in detail 
elsewher [6].  
Genetic mutations are identified in 11–28% of patients with Brugada syndrome, of which the 
majority (>90%) are located in the SCN5A gene [2]. This gene encodes the alpha-subunit of the 
cardiac sodium channel Nav1.5, which is responsible for the sodium inward current (INa). 
Mutations in other channels, or channel regulatory proteins, have also been linked to the Brugada 
syndrome. So far, more than 20 genes have been associated with this diseas [7]. These include 
genes encoding for the L-type calcium channels Cav1.2 (CACNA1c) and Cavß2b (CACNB2b)[8,9], 
glycerol-3-phosphate dehydrogenase 1-like enzyme (GPD1L)[10], β-subunits of the sodium 
channel (SCN1 [11], SCN2 [12], SCN3 [13]) and MiRP2 (KCNE3)[14], among others. However, 
disease-gene associations were recently re-evaluated by an expert consortium of the Clinical 
Genomic Resource (ClinGen). This evidence-based gene validation for Brugada syndrome 
indicated that 20 of 21 genes lack sufficient evidence to support causality for Brugada syndrome. 
Regarding clinical validity, only the SCN5A gene was classified as demonstrating definitive 
evidence as a cause for Brugada syndrome [15]. Variants in other genes may still contribute to 
susceptibility to Brugada syndrome, suggesting that this disease, initially considered as 
autosomal dominant monogenic, could actually be multigenic. In the present review, we will 
focus on models used to study Brugada syndrome related to SCN5A mutations, with limited 
mention of other genes. 
Whilst the role of loss of function of the Nav1.5 channel in Brugada syndrome is undisputed, 
there is disagreement as to the mechanism underlying the pathophysiology of this disease. Two 
main hypotheses have been proposed: The “repolarization hypothesis” based on the transmural 
dispersion of repolarization in the right ventricle (RV) between the endocardium and epicardiu 
[16]; and the “depolarization hypothesis” based on RV conduction slowing and presence of subtle 
structural abnormalitie [17]. Arguments for and against either hypothesis have been extensively 
reviewed and discusse [17,18] 
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Case studies have contributed to understanding the mechanisms underlying Brugada 
syndrome as well as to improve patient diagnosis and treatmen [3,19–21]. Although the human 
heart represents the gold standard for the study of Brugada syndrome inherent methodological 
and ethical limitations impose the need to rely on animal and cellular studies. Different models 
have been used to simulate this disease (Figure 2), including transgenic mice, canine heart 
preparations, transgenic pork, expression of mutant SCN5A in different cellular models and 
induced pluripotent stem cell-derived cardiomyocytes (iPS-CM). 
This review aims to analyze the experimental systems most commonly used to model 
Brugada syndrome. Knowledge gained from studies performed using the different models has 
contributed to our current understanding of mechanisms involved in Brugada syndrome. Here 
we discuss their major accomplishments as well as their strengths and limitations.  
 
Figure 2. A Schematic overview of the experimental models predominately used for studying 
Brugada syndrome. Murine Models: Generated through targeted disruption of Scn5a. 
Manipulated ES cells are transfected into blastocysts to give rise to a male chimera. Crossing with 
wild type females results in heterozygous offspring (Scn5a+/−). Canine Models: Wedges of canine 
left or right ventricles are perfused arterially. Brugada syndrome is drug-induced with Na+-
channel blockers (e.g., pilsicainide), Ca2+-channel blockers (e.g., verapamil) or K+-channel 
openers (e.g., pinacidil), which are administered either by themselves or in combination. 
Expression Systems: Families displaying symptoms of Brugada syndrome are screened for 
mutations using direct sequencing with a candidate gene approach. Relevant mutations are then 
introduced into vectors carrying the gene of interest using site-directed mutagenesis, and 
subsequently transfected into a host cell (e.g., tsA201 cells) or in vitro transcribed and injected 
into Xenopus oocytes. Cardiomyocytes from Induced Pluripotent Stem (iPS) Cells: Dermal 
fibroblasts are isolated, cultured and transfected with the pluripotency factors Oct3/4, Klf4, Sox2, 
and c-Myc. Transfected fibroblasts are then cultured in human embryonic stem cell selection 
media until colonies of iPS cells are detected. Selected iPS cells then undergo cardiomyocyte 
differentiation using either unguided (spontaneous) differentiation, guided differentiation 
(cytokines, growth factors) or through co-culture. The parameters analyzed and key findings for 
each model system are summarized at the bottom of each panel. 
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2. Murine Models 
Two approaches have been conceived. In one, the murine equivalent of the human SCN5A 
gene (Scn5a) is knocked out to simulate a generic Brugada syndrome phenotype. In the other, a 
specific mutation found in a family with Brugada syndrome is introduced to replicate this 
particular phenotype. 
2.1. Scn5a Heterozygous Knockout Mice 
In 2002, Papadatos et al.[22] generated a mouse model for arrhythmias through targeted 
disruption of Scn5a (Figure 2). Homozygous knockout mice exhibited embryonic lethality due to 
structural abnormalities of the heart. Heterozygous knockout mice (Scn5a+/−) were 
indistinguishable from their wild type (WT) littermates with regards to weight, heart/body 
weight ratio and cardiac morphology. The electrocardiogram of Scn5a+/− mice revealed slowed 
conduction compared to WT mice, but a normal QT-interval. Whole-cell patch-clamp recordings 
confirmed these findings and demonstrated a ~50% reduction in Na+ conductance, explaining 
impaired action potential propagation, conduction block, re-entrant arrhythmias and ventricular 
tachycardia in this model. However, Scn5a+/− mice exhibited several cardiac phenotypes as 
opposed to one strictly representative of the Brugada syndrome. Phenotypic heterogeneity in 
Scn5a+/- mice as well as in patients carrying SCN5A mutations is considerable, even resulting in 
some symptom-free mutation carriers. This heterogeneity could at least in part be explained by 
varying levels of Nav1.5 protein expression, with the severity of the phenotype correlating with 
expression levels of Nav1.5[23]. 
The mouse model described in this initial report was subsequently used to investigate how 
far it recapitulates clinical phenotypes observed in Brugada syndrome patients, to assess drug 
response, and to examine the underlying mechanisms of those phenotypes observed. Age and 
sex-related factors in disease progression such as an increased risk of cardiac-related mortality, 
and AV node conduction disease and bradycardia in old males have been replicate [24–28]. 
Studies aiming to recapitulate the response of Brugada syndrome patients to pro- and anti-
arrhythmic drugs showed that in Langendorff-perfused Scn5a+/− hearts, flecainide increased RV 
transmural gradients while quinidine decreased them, in line with their respective pro- and 
antiarrhythmic effect [29–31]. Anesthetized WT and Scn5a+/− mice were also used to record 
electrocardiograms which revealed that ventricular arrhythmias, ST-segment elevation, 
transmural repolarization gradients and abnormal conduction present in these animals were 
accentuated by treatment with flecainid [32].  
Martin et al.[33] used the mouse model to investigate molecular and functional differences 
between RV and left ventricle (LV) in the Scn5a+/− compared to the WT heart. Nav1.5 mRNA and 
protein expression were lower in Scn5a+/− than in wild-type (WT) animals, with a further 
reduction in the RV compared to the LV. Action potential upstroke velocity and maximum Na+ 
current density were correspondingly decreased in Scn5a+/−, with a further reduction in the RV 
compared to the LV. The initial reduction in Nav1.5 expression was confirmed by Zhang et al.[34]. 
These authors also investigated the characteristics of the ventricular effective refractory periods, 
conduction velocities and dispersion in conduction direction in relation to this decreased Nav1.5 
expression. This was further related to the appearance of fibrosis. Recently, this has been 
thoroughly reviewed by Huan [35]. 
Although many of the results obtained using the Scn5a+/− mice support the depolarization 
hypothesis, some contradictions among the above-mentioned studies (editorialized by Tse et 
al.[36,37]) complicate their interpretation to reach a clear conclusion on the mechanism leading 
to arrhythmogenesis in Brugada syndrome.  
Interestingly, a recent study by Kelly et al.[38] showed that normal structural heterogeneities 
present in the RV are sufficient to explain the susceptibility to arrhythmias when sodium current 
is diminished. Using optical mapping and two-photon microscopy in isolated-perfused mouse 
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hearts, this state-of-the-art study strengthens the claim that the mouse model can faithfully 
recapitulate the Brugada syndrome phenotype, especially when a mutation in SCN5A is present.  
2.2. Scn5a-1798insD Knock-in Mice 
One of these mutation-specific mouse models was developed by Remme and coworker [39], 
who generated a mouse strain carrying the murine equivalent of the human SCN5A-1795insD 
mutation. This mutation had been identified in different members of a Dutch family, who display 
overlap symptoms of Long QT syndrome 3 (LQT3), Brugada syndrome and progressive cardiac 
conduction defect [40]. Mice carrying the Scn5a-1798insD mutation indeed showed a similar 
phenotype demonstrating bradycardia, QT prolongation, and right ventricular conduction 
slowing, confirming that a single mutation was sufficient to cause the overlap syndrome. 
Interestingly, the severity of the conduction defect caused by the Scn5a-1798insD/+ was shown to 
be strain dependen [41]. This correlated with a lower β4 subunit expression in ventricular tissue 
resulting in a larger loss of function of Nav1.5 current in isolated myocyte [39].  
2.3. Strengths and Limitations of Mouse Models 
The advantage of using a model organism rather than a single cell expression system is that 
a mutation of interest can be investigated in its physiological environment and during different 
developmental stages. The heterozygous knockout of Scn5a in mice generated a mouse model 
that replicates many features associated with the Brugada syndrome including sex-dependent 
disease progression and drug response. Both depolarization and hypothesis were supported by 
evidence provided by this model. Thus, although it has not delivered a conclusive answer 
regarding the mechanism underlying arrhythmias in Nav1.5 haploinsufficient animals, this 
model has proved valuable for exploring the underlying cause of ventricular tachycardia in 
patients. 
Still, there are some limitations when extrapolating the repolarization findings obtained with 
the mouse model to the human heart. Besides the obvious difference in size and faster beating 
rate (four to eight times faster), they present differences in their ion channel patterns compared 
to the human heart (e.g.: TTX-sensitive sodium channels transcript levels decreased with 
increasing heart size)[42]. This different expression profile results in different action potential 
characteristics and pharmacology. 
In addition, engineering mice with patient-specific Brugada syndrome mutations is costly. 
However, as shown by the recent study by Kelly et al.[38], it is a very valuable model to 
investigate the interplay between structural and ionic factors in arrhythmogenesis, which cannot 
be investigated in most of the other available models. 
3. Porcine Model 
Despite the electrophysiological similarities between the porcine and human heart, the 
expansiveness of this model has limited its use in the research of Brugada syndrome. A work by 
Park and collaborators used hearts from pigs carrying the porcine equivalent of the human 
nonsense mutation SCN5A-E555X [44]. This [43]mutation had previously been identified in a 
patient with Brugada syndrome. They reported that hearts from the modified animals showed 
no structural abnormalities, but they displayed conduction slowing and increased susceptibility 
to ventricular arrhythmias, compared with wild type animals. These animals did not display a 
Brugada syndrome ECG pattern, their hearts were rhythmically unstable and manifested 
spontaneous or inducible ventricular fibrillation. Whether the lack of a clear Brugada syndrome 
ECG was due to the absence of fibrosis in the modified pig heart remains unresolved. 
4. Canine Models 
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Canine models have been widely used for the study of cardiac electrophysiology. Almost all 
data obtained from the canine model for Brugada syndrome were acquired using arterially 
perfused wedges of canine left or right ventricles rather than a whole heart. Perfused wedges are 
treated with drugs to induce the Brugada syndrome phenotyp [44] (Figure 2). Different drugs 
have been used to that end, all of which are either Na+ channel blockers (e.g. pilsicainid [45]), 
Ca2+ channel blockers (e.g. verapami [46]) or K+ channel openers (e.g. pinacidi [47]) and are 
administered either alone or in combination. These induced systems have been exploited to 
investigate the underlying electrophysiological cause of the different abnormalities that can be 
usually observed on the Brugada syndrome electrocardiogram. Canine heart experiments have 
been key in understanding several arrhythmia-related ECG landmarks, such as ST-segment 
elevation, the J-wave/Osborne wave, and T-wave alternans and ventricular tachycardia or 
fibrillation. 
4.1. Use of Canine Models to Uncover the Biophysical Causes of the Alterations in the Electrocardiogram 
4.1.1. The J-wave/Osborne Wave 
The J-wave, also called Osborne wave, is a positive deflection located between the QRS and 
ST-segment on the electrocardiogram (Figure 1) and is found in patients at risk of ventricular 
fibrillation such as those with Brugada syndrome. Drug-induced canine heart preparations were 
first proposed as a suitable model system for the Brugada syndrome in 1996 when Yan and 
Antzelevitch investigated the underlying cause of the J-wav [44]. Transmembrane action 
potential recordings suggested a voltage gradient across the ventricular wall. Similar results 
could be achieved by cooling the right ventricular outflow tract in sit [48], providing a possible 
in vivo model. 
4.1.2. The ST-Segment Elevation 
ST-segment elevation is the most striking feature and the primary criteria used for diagnosis 
of a patient with classical Brugada syndrome. Several groups have pursued investigations to 
define the electrophysiological alterations that result in ST-segment elevation during ventricular 
repolarization. Yan and Antzelevitch used flecainide and acetylcholine to induce Brugada 
syndrome in a canine model. This approach allowed them to propose that ST-segment elevation 
is caused by the same transmural voltage gradient across the right ventricular wall that causes 
the J-wav [16,44]. The transmural voltage gradient is caused by depression or loss of the epicardial 
action potential dome. Their results also indicated that phase 2 reentry (P2R) could cause extra-
systolic activity in the right ventricular wall which could serve as a substrate for ventricular 
arrhythmias. ST-segment elevation had previously been linked to electrical heterogeneity in the 
recovery phase, a substrate for P2 [45]. Thus, this model has provided evidence showing that 
transmural dispersion of ventricular repolarization leads to ST-segment elevation. Further 
experiments have shown that repolarization abnormalities associated with ST-segment elevation 
are located in the right ventricular outflow tract [49,50]. This last study showed that epicardial 
heterogeneity of action potential induced transmural heterogeneity of action potential, 
contributing to P2R and ventricular tachycardia.  
4.1.3. T-Wave Alternans and Ventricular Tachycardia or Fibrillation 
Another feature of the Brugada phenotype associated with loss of the action potential dome 
is T-wave alternans. This arises due to beat-to-beat variation in amplitude, polarity, and 
morphology of the T-wave, and has been associated with an increased risk of ventricular 
arrhythmia. Morita et al. [51]  were the first to describe its electrophysiological foundation and 
showed that it is at least in part caused by the same increased dispersion of repolarization that 
causes ST-segment elevation. Later, Fish and Antzelevitch [52] showed that T-wave alternans 
share another feature with ST-segment elevation. The results from a right ventricular wedge 
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preparation perfused with verapamil, a sodium and calcium channel blocker, indicated that T-
wave alternans could be caused not only by the loss of the action potential dome but also by a 
concealed P2R which both lead to transmural dispersion of repolarization. Whilst mutations in 
both the cardiac sodium- or calcium-channel may cause Brugada syndrome, there are phenotypic 
differences between the [51]. The interpretation of data generated from model systems using a 
combined sodium-calcium channel block approach is therefore challenging. 
4.2. Use of Canine Models to Assess the Cause for Sex Differences 
One interesting aspect about Brugada syndrome is that even though mutations causing the 
disease are equally inherited by males and females, males are 8-10 times more likely to develop 
symptom [52]. Recordings performed in cardiomyocytes isolated from canine epicardium have 
shown a smaller transient outward potassium current (Ito) density in females compared to males. 
This reduced Ito could protect females from developing Brugada syndrome, but make them more 
prone to progressive conduction problems when inward currents like INa are compromise [53]. 
4.3. Use of Canine Models to Identify Markers of Risk and to Improve Treatment 
Even though discovering the mechanisms that lead to ventricular arrhythmias is important, 
the ultimate goal remains to apply the gathered knowledge to improve methods for diagnosis, 
prediction of high-risk patients and treatment. Investigations of conduction abnormalities, such 
as right bundle branch block, led to the discovery of fragmented QRS as a new marker for 
Brugada patients with a high risk of syncope and developing spontaneous ventricular fibrillatio 
[54]. Fragmented QRS are conduction abnormalities within the QRS complex and can manifest as 
multiple spikes in the QRS segment. In terms of treatment, most strategies aim at preventing 
sudden death caused by ventricular arrhythmias rather than treating the underlying cause, i.e., 
loss of sodium channel function. Using the canine model, researchers were able to show that a 
more focused application of radiofrequency catheter ablation (RFA) to the epicardium might be 
more efficient in eradicating ventricular tachycardia in Brugada syndrome patient [55]. A more 
recent study showed that the beneficial effects of RFA are based on destroying the cells with the 
most prominent action potential notch in the epicardial surface. The authors conclude that RFA 
eliminates sites of abnormal repolarization and therefore the substrate for ventricular tachycardia 
and ventricular fibrillatio [56]. These examples illustrate how the canine model system could help 
not only to find new, easy to measure, markers for high-risk patients but also suggest possible 
improvements for established treatments. 
4.4. Strengths and Limitations of the Canine Model 
Canine preparations have proven to be a useful system for modeling Brugada syndrome. 
Not only have they linked J-waves, ST segment elevation and T-wave alternans to a depression 
of the action potential dome, they were also instrumental in determining that a lower Ito density 
in females compared to males, could protect females from developing Brugada syndrome. In 
addition, the canine model helped reveal fragmented QRS as a new marker for high-risk patients 
and suggested a novel method of using radiofrequency ablation in Brugada syndrome patients. 
The main advantage of using the heart wedge preparation is that cells in epi- and endocardium 
can be investigated preserving their structural organization within the heart.  
An apparent limitation of the canine coronary perfused wedge preparation is that it does not 
include the RVOT making it difficult to test the hypothesis of depolarization as the underlying 
mechanism for arrhythmogenesis in Brugada syndrome patients. Nevertheless, by using NS5806 
in conjunctions with verapamil on this model to mimic the Brugada syndrome phenotype, Szél 
and Antzelevitc [20] showed that late potentials and fractionated electrogram arise from 
heterogeneities in the epicardial action potential. They also showed that high-frequency spikes 
appear as a result of concealed phase-2-reentry. The authors argue that no primary conduction 
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delay was observed as the cause of the Brugada syndrome ECG phenotype or late potential or 
fractionated electrogram activity. This evidence supports the hypothesis that primary 
repolarization defects are responsible for the Brugada syndrome phenotype. 
Still, the most obvious limitation of this system is that the Brugada syndrome phenotype is 
drug-induced. Combinations of sodium and calcium channel blockers and/or potassium-channel 
openers have been used, even though the majority of patients only carry one mutation. 
Experiments have also shown subtle differences in phenotypes depending on which channel is 
bearing the mutation. Because the Brugada syndrome phenotype in this model is drug-induced, 
drug screening is limited not only due to possible interactions with the channel blocking agent 
but also because mutations underlying Brugada syndrome may be more complex than simple 
loss-of-function modeled by a drug-induced Brugada syndrome phenotype. Unfortunately, it 
also does not allow for investigations of either atypical Brugada syndrome patients with no 
mutation but a Brugada phenotype, or vice versa.  
5. Expression Systems 
Experiments using expression systems aim at deciphering the biophysical properties of both, 
wild type and mutant ion channels in single cells. This may help in understanding the molecular 
mechanisms underlying Brugada syndrome. Plasmids for the expression of genes carrying 
mutations identified in Brugada syndrome patients are typically transfected into human 
embryonal kidney, SV40 transformed (tsA201) or Chinese hamster ovary (CHO) cells. In addition, 
frog oocytes have been widely used for heterologous expression of ion channels (Figure 2). 
Xenopus laevis oocytes are large and cheap to maintain and manipulate, both of which make 
them a desirable tool for electrophysiological experiments. tsA201 are the traditional gold 
standard for ion channel characterization in mammalian single cells. Employing expression 
systems, investigators have been able to study the biophysical consequences of Brugada 
syndrome-associated mutations and the effects of external factors on sodium current.  
5.1. Use of Expression Systems to Assess the Biophysical Consequences of Brugada Syndrome-Associated 
Mutations 
Mutations in SCN5A and other genes associated with Brugada syndrome have been studied 
using expression systems. In general, these studies revealed a loss of function of sodium channels. 
Over the decades, the benchmark technique to investigate the nature of mutation-induced loss of 
function has been the combined approach of patch clamp experiments and heterologous 
expression system. This approach is uniquely suited for detailed analysis of channels’ biophysical 
properties. This type of experiments revealed that loss of sodium channel function may result 
from reduced current density, positive shifts in the voltage dependence of activation or negative 
shift in steady-state inactivation. Loss of function can also result from acceleration of inactivation 
kinetics. In addition, once the channel enters the inactivated state, it needs time to return to a state 
that permits its activation. This time, measured as the recovery from inactivation, is directly 
related to the refractory period. Thus, changes in this recovery time caused by a mutation may 
create a substrate for arrhythmogenicity.  
Since the focus of this review is to discuss the strengths and limitations of model systems, 
only a few selected studies will be used to highlight the main mechanisms through which 
mutations can cause Brugada syndrome. A comprehensive list of SCN5A mutations studied in 
heterologous expression systems, identified in Brugada syndrome patients, and their functional 
consequences are provided in Supplementary Table. A schematic representation of the location 
of these mutations within Nav1.5 is illustrated in Figure 3. A systematic pathogenicity analysis of 
all SCN5A Brugada syndrome variants has been recently reported by Denham et. a [57].  
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Figure 3. Nav1.5 channel scheme showing the location of mutations in SCN5A identified in 
patients with the Brugada syndrome. Only missense mutations that have been functionally 
characterized using expression systems are displayed. Nonsense and insertion or deletion 
mutations are not shown. Mutations found to cause a complete loss of INa are dark grey, those 
reported to reduce INa and/or alter Nav1.5 properties are light grey, and white indicates no 
changes in channel properties. Mutations for which two different types of alterations have been 
described are displayed in both colors. 
5.1.1. Sodium Current Density  
Around one-third of the Brugada syndrome-associated mutations in SCN5A that have been 
functionally characterized cause a partial reduction in sodium current density, typically 
estimated from peak INa (Supplemental Table). This reduction may arise from defects in channel 
trafficking or non-conducting channels. Trafficking defects and truncated proteins have both 
been linked to loss of function of Nav1.5 in Brugada syndrome patients. Depending on the 
mutation, expression in Xenopus oocytes or tsA201 cells can give rise to contradictory 
observations. One such example is R1432G, which completely abolished functional expression of 
sodium channels in tsA201 cells while producing slightly reduced sodium current when 
expressed in Xenopus oocytes. Mutant channels in tSA201 cells were shown to be localized in the 
endoplasmic reticulum suggesting that the mutation prevents the transport of Nav1.5 to the cell 
surfac [58]. This would be a potential mechanism for Brugada syndrome in patients with this 
mutation.  
Besides disruption of protein transport to the cell membrane, mutations that result in 
complete loss of Nav1.5 current may arise from defects in protein expression. Some mutations 
found in Brugada patients, such as E473X and N1774delT, produce truncated proteins unable to 
generate detectable sodium curren [59]. When these mutant channels were heterozygously 
expressed with wild type channels, a 50% reduction of sodium current was detected. This 
reduction, together with the absence of effects on activation or inactivation properties or on 
current kinetics, indicated that only the wild type channels were functiona [60].  
5.1.2. Voltage Dependence of Activation and Steady State Inactivation 
The reduction in peak INa can be accompanied by alterations in sodium channel properties. 
For example, the mutation SCN5A-1795insD produced a negative shift of the steady-state 
inactivation and positive shift of the steady-state activation curve [61,62]. Another example was 
shown in our work with the Nav1.5 mutation I890T. This mutation caused a reduction of current 
density together with a positive shift of the activation curve, accentuating the loss of functio [63]. 
5.1.3. Inactivation Kinetics 
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Mutations can alter the speed of inactivation resulting in accelerated or decelerated 
inactivatio [64,65]. Whereas a faster current decay reduces the net sodium current, a feature 
linked to Brugada syndrome, slower current decay is generally associated with LQT3. However, 
Brugada syndrome-associated mutations can also produce sodium currents with slower decay in 
combination with reduced peak current or, with altered activation and/or inactivation dependenc 
[65–67]. 
5.1.4. Recovery from Inactivation 
Lastly, prolonged recovery from inactivation could lead to arrhythmias in Brugada patient 
[68].  In a study of the Nav1.5 mutation 1795insD expressed in tsA201 cells, Veldkamp and 
collaborators proposed that some mutant channels enter an intermediate state of inactivation 
from which they recover slower than wild type channel [69]. This mechanism, although already 
known, had not been previously associated with Brugada syndrome. Other mutations were 
shown to have similar effects. A lengthening in the recovery from inactivation time was also 
reported for the Nav1.5 mutation T1620M. These results were however restricted to expression in 
tsA201 cells, whereas Xenopus oocytes transfected with the same mutation showed the opposite 
phenotyp [70].  
5.1.5. Other Genes Associated with Brugada Syndrome 
Although mutations have been identified in genes other than SCN5A, only a few have been 
functionally studied. Mutations in SCN1 [11], SCN2 [12], SCN3 [13] and GPD1 [10] have been 
shown to cause a reduction in sodium current, in some cases due to disruption in trafficking of 
Nav1.5 to the cells surfac [13]. Also, a mutated MiRP2 has been reported to trigger an increased 
Ito intensit [14]. Two mechanisms have been associated with mutated CACNA1c or CACNB2b 
found in Brugada patients, and while both result in loss of function, one is caused by reduction 
of L-type Ca2+-current, and the other one triggers accelerated inactivation of Ca2+ curren [9]. 
5.2. Strengths and Limitations of Expression Systems 
For a long time, expression systems were the only Brugada syndrome model that permitted 
investigation of the molecular mechanism of mutations found in patients rather than looking at 
manifestations of generic SCN5A knockout or drug-induced Nav1.5 block. Cell-based model 
systems are inexpensive and relatively easy to maintain and manipulate. Although multiple 
genes have been associated with Brugada syndrome, the genetic cause for two-thirds of all 
patients remains unidentified. The limitation of this model system is its restriction to the 
examination of known genetic causes. It also gives no insight into the heterogeneity of 
phenotypes between family members carrying the same mutation. One intriguing issue is the 
contradictory results from the expression of mutant channels in different cell lines. Even though 
both tsA201 cells and Xenopus oocytes expressing Nav1.5 are able to generate sodium currents, 
they are morphologically and functionally very different. This could explain the discrepant 
results obtained when analyzing the effects of one particular mutation using both cellular 
systems. More importantly, it is irrefutable that neither of these two cell models closely resembles 
human cardiomyocytes. Nevertheless, expression systems can still be very informative on the 
possible pathogenic effect of individual mutations. 
6. Induced Pluripotent Stem Cell-Derived Cardiomyocytes (iPS-CM) 
Yamanaka and colleague [71] provided an alternative for ethically difficult human 
embryonic stem cell research that has transformed disease modeling. Yamanaka and others 
demonstrated that somatic cells can be reprogrammed by the introduction of a number of 
transcription factors involved in pluripotency and proliferatio [43,72]. The resulting 
reprogrammed cells are almost indistinguishable from embryonic stem cells in morphology, 
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surface markers, gene expression and ability to differentiate into cells from all three germ layers. 
The great advantage of this technique is that cells carrying the desired genetic profile can be 
obtained directly from the patient, reprogrammed into iPS cells and differentiated to the specific 
cell type that is affected by the disease, e.g., cardiomyocytes (iPS CM). This technique allows 
investigators to study the mutant proteins in their native environment, which includes 
modulatory proteins.  
To date, independent studies have shown that iPSC-CMs can effectively recapitulate 
inherited arrhythmia syndromes at the cellular level. Several cardiac disorders including 
LQT1[73], LQT2[74], CPV [75] and Timothy syndrom [76] have been modelled using the iPS cell 
approach. The first Brugada syndrome mutation studied in iPS-CM was the SCN5A_1795insD 
mutatio [40]. This mutation causes a Brugada /LQT3 overlap syndrome that had previously been 
studied in both a mouse model and cell expression systems. These iPS cell-derived 
cardiomyocytes recapitulated the decrease in peak INa and persistent INa associated with Brugada 
syndrome and LQT3 respectively. 
Despite being a relatively recent experimental approach, several research groups have 
already used iPS-CM derived from Brugada syndrome patients to explore novel therapeutic tools 
and to study basic mechanisms of the disease. The following paragraphs summarize the major 
findings of these studies. 
Kosmidis et. al. [77] explored the therapeutic potential of drugs that induce translational 
readthrough of premature stop codons to reverse the effect this type of mutations in SCN5A. The 
patient-derived iPS-CM used in this study carried the Nav1.5 mutations R1638X or W156X, which 
cause a loss of sodium channel function. The study concluded that neither gentamicin nor PTC124 
were effective in reversing the effect of either mutation. These drugs, however, had been proven 
effective in restoring protein expression of other mutations. Thus, this work corroborates the use 
of patient-derived iPS-CM as a unique model to study SCN5A therapeutic tools for particular 
nonsense mutations associated with Brugada syndrome. 
A great advantage of iPS cells is that they offer the possibility of genome editing. This was 
used by Liang et al.[78] in a study in which they compared sodium currents, action potentials and 
calcium dynamics in iPS-CM derived from two Brugada syndrome patients and two healthy 
control. The authors reported a reduced sodium current, increased triggered action potential 
activity, and abnormal Ca2+ transients in the Brugada syndrome patient-derived cells in one of 
the patient-derived iPS cell lines the SCN5A mutation (c.4190delA) was edited using the 
CRISPR/Cas9-mediated genome editing technology. Reversion of the mutation to wild-type 
normalized the electrical properties of the patient-derived cells, indicating that the mutation was 
sufficient to cause the defects. This study showed that the combined approach of patient-specific 
iPS-CM and CRISPR-Cas9 genome editing can be valuable to test genotype-phenotype 
associations in Brugada syndrome.  
As 70% of Brugada syndrome patients remain without an identified mutation, iPS-CM 
provide the opportunity to study the cellular mechanisms of disease in those patients and provide 
clues regarding candidate genes. Interestingly, a thorough study by Veerman et. al. [79] using 
iPS-CM derived from three Brugada syndrome patients without a known coding mutation 
showed no differences in sodium currents between patients and control-derived cells. These 
authors concluded that cellular electrophysiological changes may not participate in generating 
the clinical phenotype in these patients. This could imply that the underlying mechanism for 
these patients’ phenotype is not caused by defects in ion channels or their modulatory subunits 
but may instead involve the development of structural changes like fibrosis in the RV.  
Similar results were found by Miller et al. [80]. These authors studied Brugada syndrome-
derived iPS-CM from patients with no identified pathogenic mutations. Electrophysiological 
properties of these cells were indistinguishable from control-derived iPS-CM. Although this 
study demonstrated that iPS-CM were suitable to test the blocking effect of ajmaline on both 
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depolarization and repolarization, it did not find any difference of this block between Brugada 
syndrome and control-derived cells.  
One of the main disadvantages of iPS-CM as a model for arrhythmogenic diseases is their 
immature phenotype. While this seems not to be a major problem for studying most of the 
cardiomyocytes’ currents, it poses constrains on the study of action potential [81].  
To overcome this problem, Ma et al. [82] used the dynamic clamp technique to impose the 
absent inward rectifier current (IK1) onto iPS-CM to achieve a more mature functional phenotype. 
They studied patient-specific iPS-CM carrying a compound Brugada syndrome mutation 
(p.A226V and p.R1629X), and a mild Brugada syndrome SCN5A mutation (T1620M) in iPS-CM 
commercially available. They found that the effects of the compound mutation caused a 75% loss 
of sodium current compared to iPS-CM derived from a non-carrier sibling. This decrease in 
current correlated with a reduction of the maximum upstroke velocity and action potential 
amplitude. In addition, they observed early repolarization (shortening of action potential 
duration, APD) in 25% of the patient-specific derived cells paced at 0.1 Hz. Conversely, they 
found that iPS-CM with no reduction in sodium current, including controls and iPS-CM with the 
mild mutation, had normal action potential properties. This study also compared Ito levels at 
different pacing frequencies and found that iPS-CM from Brugada syndrome and control-derived 
cells were equally heterogeneous regarding this current. The authors used the Ito blocker 4-AP to 
restore APD in the Brugada syndrome patient-derived iPS-CM that showed a reduction in APD 
to demonstrate the contribution of this current to early repolarization. Thus, this model showed 
that a coordinated role of Ito and loss of sodium current induces arrhythmogenic APD changes as 
it had been previously demonstrated in other Brugada syndrome models.  
Our laboratory has been using patient-specific iPS-CM to study SCN5A mutations related to 
Brugada syndrome. Our results showed that iPS-CM from a Brugada syndrome patient bearing 
the mutation p.R367H recapitulated the loss of function of Nav1.5 associated with the disease. 
More interestingly, we observed that in addition to decreasing sodium current, this mutation 
affected both, current activation and inactivation voltage-dependence, and caused a faster 
recovery from inactivation. These changes were surprising for a mutation previously described 
as non-conducting. Interestingly, when the channel was expressed in heterozygosity in tSA201 
cells, only the reduction in current density observed in iPS-CM was reproduce [83]. A possible 
explanation for this is that Nav1.5 regulatory proteins that affect channel activity and that are 
present in iPS-CM but absent in tSA201 cells.  
6.2. Strengths and Limitations of iPS-CM 
The iPS cell-based model system has great strengths, especially compared to the expression 
systems, but also has its limitations. One of its main advantages is that patient-specific iPS-CM 
not only carry the patient’s exact genetic background but also reproduce the cardiomyocytes’ 
particular properties. Considering haploinsufficiency of Nav1.5 as a key mechanism in Brugada 
syndrome, patient-derived iPS-CM offer a unique advantage since the transcriptional activity of 
these cells occurs free of experimental artifacts inherent to heterologous expression systems. 
Thus, the use of patient-derived iPS-CM models avoids potential misinterpretations arising from 
poorly controlled transcription levels. 
One of the main disadvantages that iPS-CM present, as mentioned earlier, is their immature 
phenotype, as exemplified by their characteristic spontaneous beating. Their membrane potential 
is depolarized compared with adult cardiomyocytes, and their ultrastructural organization is 
poor regarding sarcomere and t-tubule development. Accordingly, they exhibit a gene expression 
profile similar to fetal cardiomyocyte [84].  
Important progress in overcoming this limitation has been recently achieved. Ronaldson-
Bouchard et. al.[85] demonstrated that formation of tissues from early-stage iPS-CMs followed 
by electromechanical stimulation yielded iPS-CM with adult-like gene expression profile and 
organized ultrastructure, together with the development of t-tubules and functional calcium 
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handling. These cells also presented an action potential shape with a characteristic notch, a resting 
membrane potential around -70 mV and, importantly, the presence of the IK1 current. 
Another advantage of the iPS cell-based model system is that it offers the most accurate and 
relevant setting for drug toxicity screening of all the model systems, which could help exclude 
potential drugs, based on their toxic effects on cardiomyocytes before they go into expensive 
clinical trials. Lastly, since iPS cell lines are immortal and do continually express the mutant 
channel (unlike expression systems), they can be shared between groups, allowing for new 
collaborations and more in-depth characterization. 
However, the generation of iPS cells requires ethical approval. Although it is possible to 
obtain beating clusters or sheets composed of ventricular, atrial and pacemaker cell [86], they are 
not organized in layers of endocardium and epicardium, and it is difficult to purify populations 
of ventricular or atrial cells. However, methods have been developed to direct differentiation 
towards a specific cardiac subtype by manipulating retinoid signal [87]. Identification of the cell 
surface marker VCAM1 [88] also made it possible to purify and reassemble iPS derived cardiac 
cells in cardiac tissue sheets with a possible application in cell therapy.  
Finally, because iPS-CM do not come from a heart, it would be arguable to attribute to them 
chamber-specific characteristics such as RV or LV, or layer-specific characteristics (epicardium or 
endocardium). This limits the interpretation of the data obtained from this model since Brugada 
syndrome is a chamber (RV)-specific disease.  
7. Conclusions 
Brugada syndrome is a heterogeneous condition with an unpredictable clinical course. 
Several experimental approaches have been used to define the underlying mechanisms of this 
life-threatening disease. The major findings, advantages, and disadvantages of each model 
included in this review are summarized in Table 1. 
The role of a defective sodium current as an underlying pathophysiological mechanism is 
apparent in all the models used. Many SCN5A mutations have been studied in heterologous 
expression systems, and the observed sodium current loss of function greatly agreed with the 
clinical findings. However, incomplete penetrance is perhaps the main interrogate remaining.  
Whole animal models coincide in that the associated arrhythmias originate in the RVOT. 
Furthermore, increasing evidence shows that microstructural abnormalities occur in this area of 
the heart, which may lead to conduction defects. These abnormalities cannot be observed in the 
canine wedge preparation model, in which the repolarization hypothesis is based. Thus, although 
differences in epicardial and endocardial AP may contribute to the development of the 
arrhythmia, it is probable that these differences do not explain the pathophysiology entirely. It is 
important to remark that in the canine wedge model pharmacological tools are needed to induce 
arrhythmias. 
One of the unsolved questions about BrS is the lack of known genetic mutations in 
approximately 70% of the diagnosed patients. Numerous efforts have been made to find genes, 
other than SCN5A, implicated in the disease. Despite experimental evidence supporting the role 
of more than 20 genes in BrS, their role as the monogenetic cause of this disease is being disputed 
[89]. Moreover, increasing evidence suggests that BrS is an oligogenic disease, in which a 
combination of several genetic factors with different degrees of effect sizes underlie the clinical 
phenotype [90]. 
The development of iPS-CM as a model to study BrS brought the opportunity of delving into 
detailed cell physiology of cardiomyocytes derived from actual mutation carriers and/or 
diagnosed patients without an identified genetic cause. Several laboratories, including ours, have 
shown evidence for the loss of function of the sodium channel in carriers of mutations in SCN5A 
[77,78,82,83]. For instance, it was expected that cells from BrS patients showed abnormalities in 
sodium current properties, even if the patient did not have a mutation in SCN5A (e.g., mutations 
in non-coding regions leading to low expression of the protein). However, this was not observed 
Int. J. Mol. Sci. 2019, 20, 2123 14 of 22 
 
in two different studies using iPS-CM derived from this type of patients [79,80]. This could imply 
that the clinical manifestation of the disease may occur in the absence of any dysfunction of the 
sodium current. In other words, this may suggest that, at least in some cases, BrS may no longer 
be considered a channelopathy. Whether this holds true for the large majority of BrS cases (i.e., 
those with no genetic defects) remains to be determined. In that sense, we believe iPS-CM studies 
will be critical in redefining the etiology of BrS. Still, these findings do not rule out that a transient 
physiological impairment of the sodium current may trigger arrhythmia in a susceptible 
individual. As more studies on iPS-CM appear, we will be able to better understand the 
pathophysiology of BrS at the cellular level. We expect that iPS-CM will help answer unresolved 
interrogates like whether incomplete penetrance is caused by protein interactions particular to 
each individual genetic background. Furthermore, a larger number of studies on iPS-CM from 
BrS patients with the negative genetic test may reveal abnormalities in their cellular phenotype.  
It is clear that the whole animal and/or whole organ studies are needed to fully understand 
the occurrence of arrhythmias. iPS-CM are likely to help in re-thinking animal models that better 
recapitulate the diversity of phenotypical patterns. 
In summary, defining the cellular mechanisms that lead to the disease will help us 
understand differences in clinical outcomes between patients and the role of modifier genes. 
However, with more than 400 genetic alterations associated with Brugada syndrome, this poses 
an enormous challenge. Complimentary in vitro and in vivo models have added to our 
understanding, but a validation of these models using patient-specific iPS-CM will help reveal 
the true consequences of different mutations for individual patients. Functional characterization 
of cardiomyocytes from iPS cells bearing specific mutations will provide novel insight into the 
mechanisms and pathophysiology of this condition and may offer opportunities to improve the 
diagnosis and treatment of patients with Brugada syndrome.  
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Table 1. Summary of the main findings, advantages, and disadvantages of the experimental 
models used for studying Brugada syndrome. 
Model Major Findings Advantages Disadvantages 
Murine 
SCN5A+/− mouse:  
• ~50% reduction in 
INa, slowed conduction, 
conduction block, re-entrant 
arrhythmias and ventricular 
tachycardia [22]. 
• Age and sex-related 
factors in disease progression 
[24–28]. 
• Reduced Nav1.5 
protein expression [33,34]. 
• Fibrosis-related to 
decreased Nav1.5 expression 
[34]. 
Scn5a1798insD mouse: 
• Bradycardia, QT 
prolongation and right 
ventricular conduction 
slowing [39].  
• Strain dependence of 
conduction defect caused by 
the Scn5a1798insD/+ [41].  
• Allows integral 
studies from the whole 
animal, organ, tissue, and 
single cells. 
• Ion channels can be 
knock out or modified. 
• Size and 
electrophysiological 
differences with the 
human heart. 
• Profile of ion 
channel expression 
different to the human 
heart. 
Canine 
• Correlation between 
epicardial notch AP 
amplitude and J wave 
amplitude [44]. 
• Transmural 
dispersion of repolarization 
leading to ST-segment 
elevation [16,44].  
• Repolarization 
abnormalities associated with 
ST-segment elevation are 
located in the right ventricular 
outflow tract [49].  
• Male/female 
differences in susceptibility to 
Brugada syndrome are related 
to gender differences in Ito 
[53].  
• Focused application 
of RFA to the epicardium 
might be more efficient in 
eradicating ventricular 
tachycardia in Brugada 
syndrome patients [56]. 
• Allows 
investigation of cells in 
epicardium and 
endocardium preserving 
their structural organization 
in the heart. 
• Electrophysiological 
similarities with the human 
heart. 
• Profile of ion 
channel expression similar to 
the human heart. 
• Brugada 
Syndrome phenotype 
has to be 
pharmacologically 
induced. 
Porcine 
• Conduction slowing 
and increased susceptibility to 
ventricular arrhythmias [91]  
• Lack of a clear 
Brugada Syndrome [91]. 
• Allows 
investigation of cells in 
epicardium and 
endocardium preserving 
their structural organization 
in the heart. 
• Expensive. 
• Long 
reproductive cycles. 
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• Electrophysiological 
similarities with the human 
heart.  
Heterologous 
expression 
See Supplementary Table • Relatively easy to 
perform.  
• Allows detailed 
studies of the intrinsic 
biophysical properties of ion 
channels affected by 
mutations. 
• Lack of many 
specific cardiac 
proteins. 
• Absence of 
patient-specific 
genetic background. 
• Results may 
vary according to the 
cell model (e.g.: HEK 
cells vs. Xenopus 
oocytes). 
iPS-CM 
• Reduced sodium 
current, increased triggered 
AP activity, and abnormal 
Ca2+ transients. Genome 
editing reversed the effects of 
the mutation, indicating 
causality [78]. 
• Patients with no 
mutation identified do not 
present current abnormalities 
[79,80]. 
• Decrease in current 
correlated with a reduction of 
the maximum upstroke 
velocity and AP amplitude 
[82]. 
• Mutation-induced 
changes, other than current 
density may appear in 
patient-specific iPS-CM, but 
not in heterologous 
expression recordings [83]. 
• No changes in 
sodium current were 
observed in iPS-CM from 
patients without SCN5A 
mutation [79]. 
• Patient-specific iPS-
CM carry the patient’s exact 
genetic background. 
• iPS-CM expression 
profile closely resembles that 
of cardiomyocytes. 
• iPS cells are suitable 
for genome editing. 
• Immature 
phenotype.  
• Depolarized 
membrane potential 
compared with adult 
cardiomyocytes.  
• Negligible 
levels of IK1. 
• Poor 
ultrastructural 
organization 
regarding sarcomere 
and t-tubule 
development. 
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Abbreviations 
AV node atrial ventricular node 
HEK human embryonic kidney 
iPS cells induced pluripotent stem cells 
iPS-CM induced pluripotent stem cell-derived cardiomyocytes 
LQT syndrome long QT syndrome  
P2R phase 2 reentry 
INa sodium inward current  
tsA201 cells immortalized HEK293 cells 
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